Legend Biotech announced on August 27 that its CAR-T therapy, Kawa Di, has been approved by the National Medical Products Administration (NMPA) for the treatment of relapsed or refractory multiple myeloma (R/R MM) in adult patients who have previously received at least third-line therapy (including the use of a proteasome inhibitor and an immunomodulatory agent).
传奇生物：CAR-T疗法卡卫荻获国家药品监督管理局批准上市
Legend Biotech: CAR-T therapy Cardiwell has been approved for marketing by the National Medical Products Administration.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated